Soleno Therapeutics (SLNO) Price & Analysis

Compare

876 Followers

SLNO Stock Chart & Stats

$49.55

-$1.55(-3.35%)

At close: Jan 08 4:00 PM EST

$49.55

-$1.55(-3.35%)

Day’s Range― - ―

52-Week Range$41.50 - $90.32

Previous CloseN/A

Volume118.06K

Average Volume (3M)2.11M

Market Cap

$2.66B

Enterprise Value$3.27B

Total Cash (Recent Filing)$498.93M

Total Debt (Recent Filing)$2.81M

Price to Earnings (P/E)―

Beta0.50

Next Earnings

Mar 11, 2026

EPS Estimate

0.61

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.47

Shares Outstanding53,710,026

10 Day Avg. Volume1,694,369

30 Day Avg. Volume2,105,317

Financial Highlights & Ratios

PEG Ratio-0.12

Price to Book (P/B)7.37

Price to Sales (P/S)0.00

P/FCF Ratio-26.05

Enterprise Value/Market Cap1.23

Enterprise Value/Revenue33.10

Enterprise Value/Gross Profit33.73

Enterprise Value/Ebitda-49.26

Forecast

1Y Price Target

$115.00

Price Target Upside132.09% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)0.15

Revenue Forecast (FY)$180.42M

Bulls Say, Bears Say

Bulls Say

Financial PerformanceSoleno achieved profitability during its first full quarter of launch with $26MM of positive net income for Q3.

Market AcceptanceThe prescriber base continues to expand, with 494 unique prescribers now administering Vykat XR and stronger-than-expected adoption among community physicians.

Sales GrowthVykat XR Q3 sales of $66MM more than doubled from the $32.7MM reported in Q2, substantially exceeding consensus of $47MM.

Bears Say

Commercialization UncertaintyThere remains considerable uncertainty around commercialization plans in Europe, and the company has not yet committed to launching the drug independently abroad versus partnering with a larger pharma company.

Discontinuation RatesDiscontinuation rates rose slightly to 8% due to adverse events and 10% overall, slightly above clinical-trial levels.

Launch DisruptionManagement described observing some apparent disruption in the Vykat XR launch trajectory following a short report published in August.

Soleno Therapeutics News

Soleno Therapeutics initiated with an Outperform at Wolfe Research

Wolfe Research analyst Kalpit Patel initiated coverage of Soleno Therapeutics (SLNO) with an Outperform rating and $75 price...

11d ago

SLNO

Soleno board authorizes $100M Accelerated Share Repurchase Agreement

Soleno Therapeutics (SLNO) announced that its Board of Directors has authorized a share repurchase and that it has...

17d ago

SLNO

Midday Fly By: Broader market bought on dip after tech selloff

Stocks are seeing a mild bounce today after investors pulled back yesterday from AI-linked stocks amid mounting concerns...

23d ago

Soleno Therapeutics falls -29.0%

Soleno Therapeutics (SLNO) is down -29.0%, or -$18.49 to $45.36. Published first on TheFly – the ultimate source...

23d ago

SLNO

Soleno Therapeutics falls -26.7%

Soleno Therapeutics (SLNO) is down -26.7%, or -$17.06 to $46.79. Published first on TheFly – the ultimate source...

23d ago

SLNO

Soleno Therapeutics price target lowered to $106 from $123 at Wells Fargo

Wells Fargo analyst Derek Archila lowered the firm’s price target on Soleno Therapeutics (SLNO) to $106 from $123...

23d ago

SLNO

Closing Bell Movers: AMD falls 4% on earnings, Trex, Pinterest down sharply

The opening hour of the evening session is seeing the continuation of investor sentiment souring on high-flying Tech...

24d ago

Soleno Therapeutics reports Q3 EPS 47c, consensus 6c

Reports Q3 revenue $66M, consensus $48.09M. The company said, “Revenue, net, from the sale of VYKAT XR for...

24d ago

SLNO

Soleno Therapeutics options imply 15.9% move in share price post-earnings

Pre-earnings options volume in Soleno Therapeutics (SLNO) is 2.6x normal with calls leading puts 3:1. Implied volatility suggests...

24d ago

SLNO

Soleno Therapeutics Announces $100M Share Buyback Plan

Soleno Therapeutics ( ($SLNO) ) has issued an update. On November 11, 2025, Soleno Therapeutics announced that its...

16d ago

SLNO

Soleno Therapeutics: Strong Q3 Performance and Market Potential Justify Buy Rating

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Soleno Therapeutics today and set a price target...

18d ago

SLNO

Soleno Therapeutics’ Financial Challenges: Navigating Risks in VYKAT XR Commercialization

Soleno Therapeutics (SLNO) has disclosed a new risk, in the Accounting & Financial Operations category. Soleno Therapeutics faces...

23d ago

SLNO

Soleno Therapeutics’ Earnings Call Highlights Growth Amid Challenges

Soleno Therapeutics (($SLNO)) has held its Q3 earnings call. Read on for the main highlights of the call....

23d ago

SLNO

Soleno Therapeutics Achieves Profitability with VYKAT XR Launch

Soleno Therapeutics ( ($SLNO) ) has released its Q3 earnings. Here is a breakdown of the information Soleno...

24d ago

SLNO

SLNO FAQ

What was Soleno Therapeutics Inc’s price range in the past 12 months?

Soleno Therapeutics Inc lowest stock price was $41.50 and its highest was $90.32 in the past 12 months.

What is Soleno Therapeutics Inc’s market cap?

Soleno Therapeutics Inc’s market cap is $2.66B.

When is Soleno Therapeutics Inc’s upcoming earnings report date?

Soleno Therapeutics Inc’s upcoming earnings report date is Mar 11, 2026 which is in 103 days.

How were Soleno Therapeutics Inc’s earnings last quarter?

Soleno Therapeutics Inc released its earnings results on Nov 04, 2025. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.058 by $0.412.

Is Soleno Therapeutics Inc overvalued?

According to Wall Street analysts Soleno Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Soleno Therapeutics Inc pay dividends?

Soleno Therapeutics Inc does not currently pay dividends.

What is Soleno Therapeutics Inc’s EPS estimate?

Soleno Therapeutics Inc’s EPS estimate is 0.61.

How many shares outstanding does Soleno Therapeutics Inc have?

Soleno Therapeutics Inc has 53,710,026 shares outstanding.

What happened to Soleno Therapeutics Inc’s price movement after its last earnings report?

Soleno Therapeutics Inc reported an EPS of $0.47 in its last earnings report, beating expectations of $0.058. Following the earnings report the stock price went down -26.594%.

Which hedge fund is a major shareholder of Soleno Therapeutics Inc?

Currently, no hedge funds are holding shares in SLNO

Soleno Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-20.66%

Trailing 12-Months

Asset Growth

102.18%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Soleno Therapeutics Inc

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Soleno Therapeutics (SLNO) Earnings & Revenues

Historic Earnings Reports

SLNO Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented significant positive developments, including strong revenue growth, profitability, and broad payer coverage for VYKAT XR. However, these were tempered by challenges such as increased discontinuation rates and the impact of a short seller report affecting market momentum.View all SLNO earnings summaries

SLNO Stock 12 Month Forecast

Average Price Target

$115.00

▲(132.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"$43","146":"$146","68.75":"$68.8","94.5":"$94.5","120.25":"$120.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$145.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$115.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$75.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,68.75,94.5,120.25,146],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.16,73.14769230769231,79.13538461538461,85.12307692307692,91.11076923076922,97.09846153846154,103.08615384615385,109.07384615384615,115.06153846153846,121.04923076923077,127.03692307692307,133.0246153846154,139.0123076923077,{"y":145,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.16,70.84,74.52,78.2,81.88,85.56,89.24,92.92,96.6,100.28,103.96000000000001,107.64,111.32,{"y":115,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.16,67.76307692307692,68.36615384615385,68.96923076923076,69.57230769230769,70.17538461538462,70.77846153846154,71.38153846153845,71.98461538461538,72.58769230769231,73.19076923076923,73.79384615384615,74.39692307692307,{"y":75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":55.86,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.23,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.63,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.22,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >